Bienvenue dans notre banque interrogeable de ressources et de documentation sur l’approvisionnement plus sécuritaire et autres sujets connexes.
Ressources
Guidelines | 2020
Clinical guidance, About pharmacists, About prescribers
Pharmacists Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About pharmacists, Stimulants, Substitution/OAT, Injecting drugs
Prescriber Guidelines for risk mitigation in BC from Vancouver Coastal Health
Guidelines | 2020
Clinical guidance, Harm reduction, Policy/Regulatory, Safer supply, About prescribers, Stimulants, Substitution/OAT, Injecting drugs
Guidelines | 2021
Clinical guidance, About prescribers, Chronic pain
Provide clinical guidance to ensure the uninterrupted access to OAT medications for patients during the COVID-19 pandemic.
Guidelines | 2020
Clinical guidance, Harm reduction, About pharmacists, About prescribers
This program guide was developed based on our experiences at two Toronto-based community health centres developing Satellite site programming out of the homes of people who use drugs.
Guidelines | 2020
Overdose, Harm reduction, Safer supply, Decriminalization/legalization, Equity, Advocacy, About PWUD, Barriers and enablers, Peer/PWLLE program involvement
Peers can provide insights into the realities of substance use and their local risk environments, and the applicability of programs and policies.
Guidelines | 2018
Equity, Peer/PWLLE program involvement
Despite a current lack of direct evidence, this document has been created to urgently combat overdose deaths. It is informed by existing research and based out of expert opinion.
Guidelines | 2020
Mortality, Clinical guidance, Harm reduction, Safer supply, About prescribers, Transitions in care/treatment, Injecting drugs, Diversion
Quebec safe supply clinical guidance for prescribers
Guidelines | 2020
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Stimulants, Substitution/OAT, Transitions in care/treatment, Injecting drugs
The clinical guideline was developed to provide key clinical recommendations, as well as clinical guidance on the provision of iOAT.
Guidelines | 2019
Clinical guidance, Policy/Regulatory, Safer supply, About prescribers, Illegal drugs, Stimulants, Transitions in care/treatment, Injecting drugs
Guidelines | 2017
Clinical guidance, Evidence base, Policy/Regulatory, About prescribers
Guidelines | 2023
Clinical guidance, Policy/Regulatory, About prescribers
Created in collaboration with peers and providers
Guidelines | 2018
About prescribers, About PWUD, Workplace, Peer/PWLLE program involvement
BC safe suply interim guidance for safe supply/COVID-19 risk mitigation during the pandemic
Guidelines | 2022
Overdose, Clinical guidance, Harm reduction, Safer supply, About prescribers, Rural/remote, Substitution/OAT, Carries/take-home doses
Guidelines | 2017
Clinical guidance, Policy/Regulatory, About prescribers, SCS/OPS
The key goal of this guide is to help harm reduction organizations and drug policy advocates hire and work with active drug users
Guidelines | 2010
Policy/Regulatory, About PWUD, Workplace, Substitution/OAT, Peer/PWLLE program involvement, Harm reduction
This resource provides information and recommendations to chronic pain practitioners and patients during the COVID-19 pandemic.
Guidelines | 2020
Withdrawal, Clinical guidance, Harm reduction, About prescribers, Chronic pain
